Ace Blend Raises $9.9 Mn To Fund Clinical Trials, Expand Nutrition Portfolio
In brief
Ace Blend, a D2C nutrition and supplements brand, raised $9.9 Mn (about ₹95 Cr) in a Series A2 round led by 3one4 Capital, with existing investor Fireside Ventures also participating. The funds will go toward clinical trials, supply chain work, R&D and new formats. Founder Shivam Hingorani said the company wants scientific evidence behind its claims. The brand sells about 14 products through its website, Amazon, Flipkart, Zepto and Blinkit, and reported 300% growth in FY26. It targets ₹250-300 Cr in annual recurring revenue over 12-18 months.
From the publisher
D2C nutrition and dietary supplements brand Ace Blend has raised $9.9 Mn (about ₹95 Cr) in a Series A2 funding…Excerpt from Inc42
Why it matters for student founders
Ace Blend shows that in supplements, trust has to be backed by evidence, such as clinical trials and batch testing. For a student founder, this means planning for proof early, not just for marketing. Its mix of owned website and marketplace sales is also a useful example of spreading sales across channels.
The headline and excerpt belong to Inc42. "In brief" and "Why it matters" are written by STARTIONS from the published story.
